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Objective: The purpose of this study was to assess the safety of S-1 in Japanese in inoper-
able or recurrent breast cancer patients.
Methods: A prospective post-marketing surveillance was performed at 313 sites in Japan in
patients with inoperable or recurrent breast cancer treated with S-1. We examined 1361 patients
between January 2006 and December 2007 with regard to the incidence of adverse drug reac-
tions graded by the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
Results: At least one adverse drug reaction was encountered by 858 patients, with an overall
incidence of 63.0% (858/1361). The incidence of Grade 3 or higher adverse drug reactions in a
descending order was 14.7% (200/1361). In this study, the most common combination drug was
trastuzumab. The overall incidence of adverse drug reactions was 63.5% (431/679 patients) in
patients treated with S-1 alone, and 55.9% (66/118 patients) in patients treated with S-1 þ tras-
tuzumab.
Conclusions: Monotherapy with S-1 or combination therapy with S-1 þ trastuzumab was well
tolerated for inoperable or recurrent breast cancer patients.
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INTRODUCTION
Breast cancer is currently curable if detected and treated early,
with a better prognosis than other cancers. However, recurrent
breast cancer is hard to cure, but can be treated to improve
symptoms and quality of life and prolong survival time.
S-1 is a formulation comprising tegafur (FT), a prodrug of
5-ﬂuorouracil (5-FU), gimeracil (CDHP), which inhibits
dihydropyrimidine dehydrogenase (a catabolic enzyme of
5-FU) and oteracil potassium (Oxo), which inhibits orotate
phosphoribosyltransferase (a kinase for 5-FU) at a molar
ratio of 1:0.4:1 (FT:CDHP:Oxo). It is currently used for the
treatment of breast cancer, gastric cancer, colorectal cancer,
head and neck cancer, non-small cell lung cancer, pancreatic
cancer and biliary cancer. S-1 is expected to be a therapeutic
option that reduces the burden on patients because it can be
administered orally on an outpatient basis, thereby reducing
the number of hospital visits (1,2).
S-1 was approved for the treatment of inoperable or recur-
rent breast cancer in 2005 and had a response rate of 41.7%
in a Phase II study involving patients previously treated with
a single regimen and 21.8% in another Phase II study invol-
ving patients who were unresponsive to taxanes (3,4).
Trastuzumab is a humanized monoclonal antibody (4D5)
designed to bind to the extracellular domain of human epi-
dermal growth factor receptor 2 (HER2). The NCCN guide-
lines recommend trastuzumab, either with or without
chemotherapy, as the ﬁrst-line treatment for patients with
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combined with ﬂuoropyrimidines, and the efﬁcacy in combi-
nation with capecitabine has been reported (6). However, the
safety of trastuzumab when used in combination with S-1
has not been studied in detail.
Data from the current post-marketing surveillance of S-1
involving Japanese patients with inoperable or recurrent
breast cancer are presented. The safety of combined treatment
with S-1 and trastuzumab was also evaluated in this article.
PATIENTS AND METHODS
PATIENTS
Patients with inoperable or recurrent breast cancer to be
treated with S-1 for 2 years from January 2006 to December
2007 were included in the surveillance.
DRUG ADMINISTRATION
S-1 was administered according to the ‘Dosage and
Administration’ section of the package insert: ‘A cycle consist-
ing of repeated oral administration at an initial dose calculated
from the body surface area twice daily (after breakfast and
dinner) for 28 consecutive days followed by a 14-day washout
period should be repeated’. After three cycles, a survey form
was collected and each item on the form was assessed.
SURVEY METHOD
A prospective post-marketing surveillance was performed at
313 sites in Japan from which approval of the director of the
site was obtained and a contract was concluded. The prior
registration form was faxed to the registration center through
the central registration system no later than the ﬁrst day of
treatment. The survey items consisted of patient background,
treatment state, concomitant medication/concurrent therapy,
clinical laboratory test and adverse events. As the key survey
items, the presence or absence of hand and foot syndrome at
the start of TS-1 treatment and its onset in each course were
surveyed. All adverse events that developed during three
cycles of treatment with TS-1 were recorded on the case
report form, and adverse events were recorded by the treating
physician through interview and by laboratory tests. Adverse
events were graded according to the Common Terminology
Criteria for Adverse Events (CTCAE, version 3.0) and tabu-
lated using MedDRA/J (ver.11.1) Preferred Term (PT). Red
blood cell counts decreased were recorded as anemia for the
assessment. Any medication or therapy used concomitantly
was recorded on the survey form.
STATISTICS
Analyses were performed using the statistical package SAS
9.1 (SAS Institute, Cary, NC, USA). A logistic regression
model was used to explore factors that may inﬂuence the
development of adverse drug reactions. The signiﬁcance
level was set at 5%.
RESULTS
PATIENTS
A total of 1468 patients from 313 institutions were enrolled
between January 2006 and December 2007. Of these, 1444
patients were treated with S-1. A completed survey form was
collected from 1420 patients. Patients who received their
ﬁrst dose before the contract of the surveillance study was
concluded were excluded. Therefore, 1361 patients were
included in the safety evaluation. The reasons for S-1 treat-
ment were inoperable/recurrent disease in 1308 patients,
adjuvant therapy in 51 patients and neoadjuvant therapy in 2
patients. Of the patients with inoperable/recurrent breast
cancer, 679 patients were treated with S-1 alone and 629
patients were treated with S-1 in combination with other
anticancer drug(s) (Fig. 1).
ADVERSE DRUG REACTIONS
The number and incidence of common adverse drug reac-
tions included in the safety evaluation are shown in Table 1.
At least one adverse drug reaction was reported by 858
patients, with an overall incidence of 63.0% (858/1361). The
incidence of Grade 3 or higher adverse drug reactions in a
descending order was 14.7% (200/1361), including neutro-
phil count decreased (4.2%; 57/1361), white blood cell
count decreased (3.4%; 46/1361), anemia (including red
blood cell count decreased, 2.5%; 34/1361), diarrhea (1.5%;
21/1361) and platelet count decreased (1.4%; 19/1361). The
incidences of other Grade 3 or higher adverse drug reactions
were lower than 1%. The number and incidence of adverse
drug reactions according to the patient characteristics are
s h o w ni nT a b l e2. Multivariate analysis using a logistic
regression model revealed that the factors such as allergic
predisposition, medical history, pre-treatment abnormal renal
function, previous therapy (radiation therapy) and initial
daily dose of S-1 per body surface area were associated with
the development of adverse drug reactions. The most inﬂuen-
tial factor was allergic predisposition, which was associated
with 3.3-fold higher risk of adverse drug reactions (Fig. 2).
HAND AND FOOT SYNDROME
A clinical trial suggested that the incidence of hand and foot
syndrome was 21.8% (12/55 patients) in previously treated
breast cancer patients (2); higher than that seen in other
cancers. In addition to adverse drug reactions as study items,
the presence or absence of hand and foot syndrome prior to
S-1 treatment, as well as the occurrence of hand and foot
syndrome during each treatment cycle, was investigated to
determine whether a similar trend was observed in this
survey. Hand and foot syndrome was reported by 113
1052 Safety of S-1 and trastuzumabFigure 1. Patients’ background.
Table 1. Number of patients with adverse drug reactions and incidence of
adverse drug reactions (ADRs)
ADRs Number of
patients with
ADRs (%)
Number of patients
with Grade 3 or more
severe ADRs (%)
Overall 858 (63.0) 200 (14.7)
Hematologic toxicity
Anemia (including red blood cell
count decreased)
174 (12.8) 34 (2.5)
Neutrophil count decreased 159 (11.7) 57 (4.2)
Platelet count decreased 138 (10.1) 19 (1.4)
White blood cell count decreased 227 (16.7) 46 (3.4)
Non-hematologic toxicity
Anorexia 85 (6.2) 10 (0.7)
Diarrhea 139 (10.2) 21 (1.5)
Nausea 90 (6.6) 7 (0.5)
Stomatitis 64 (4.7) 5 (0.4)
Vomiting 48 (3.5) 9 (0.7)
Hepatic function abnormal 54 (4.0) 7 (0.5)
Palmar–plantar erythrodysesthesia
syndrome
68 (5.0) 2 (0.1)
Rash 23 (1.7) 1 (0.1)
Malaise 31 (2.3) 3 (0.2)
Alanine aminotransferase increased 52 (3.8) 4 (0.3)
Aspartate aminotransferase increased 68 (5.0) 6 (0.4)
Blood bilirubin increased 123 (9.0) 6 (0.4)
Blood alkaline phosphatase increased 74 (5.4) 8 (0.6)
Table 2. Number of patients with ADRs and incidence of ADRs in relation
to patient characteristics
Number of
patients
Number of patients
with ADRs (%)
Age
 20 to ,30 1 1 (100.0)
 30 to ,40 44 23 (52.3)
 40 to ,50 207 135 (65.2)
 50 to ,60 459 285 (62.1)
 60 to ,70 389 263 (67.6)
 70 to ,80 216 126 (58.3)
 80 45 25(55.6)
PS
0 835 517 (61.9)
1 397 261 (65.7)
2 100 61 (61.0)
3 21 14 (66.7)
4 8 5 (62.5)
Purpose of use
Inoperable 137 81 (59.1)
Recurrent 1171 746 (63.7)
Post-operative adjuvant therapy 51 30 (58.8)
Pre-operative therapy 2 1 (50.0)
Allergic predisposition
No 1307 815 (62.4)
Continued
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dence of 8.3% (113/1361 patients). Eighty patients with no
pre-treatment ﬁndings experienced hand and foot syndrome
after the initiation of S-1 treatment; an incidence of 6.2%
(80/1300 patients).
SAFETY EVALUATION OF PATIENTS
TREATED WITH S-1 1 TRASTUZUMAB
PATIENT CHARACTERISTICS
S-1 alone was used to treat 679 patients with inoperable/recur-
rent breast cancer and in combination with other anticancer
drug(s) in 629 patients. The most common combination was
S-1 þ trastuzumab (118 patients), followed by anastrozole
(84 patients), letrozole (80 patients) and exemestane (71
patients). The characteristics of the patients treated with S-1
alone and of those treated with S-1 þ trastuzumab are shown
in Table 3. There were signiﬁcant differences in expression of
hormone receptor and/or HER2, complications and previous
therapy (chemotherapy or hormone therapy). The median dur-
ation of treatment with S-1 was not signiﬁcantly different
between patients treated with S-1 alone (59 days) and those
treated with S-1 þ trastuzumab (66 days).
COMPARISON OF ADVERSE DRUG REACTIONS BETWEEN S-1
ALONE AND S-1 þ TRASTUZUMAB
The most common adverse drug reactions recorded in
patients treated with S-1 alone or with S-1 þ trastuzumab are
s h o w ni nT a b l e4. The overall incidence of adverse drug
reactions was 63.5% (431/679 patients) in patients treated
with S-1 alone and 55.9% (66/118 patients) in patients
treated with S-1 þ trastuzumab. There were no marked
differences in the incidence of other adverse drug reactions
between the two groups.
DISCUSSION
We set out to determine whether monotherapy with S-1 or
combination therapy of S-1 and trastuzumab would be effec-
tive in the treatment of breast cancer. With the remarkable
progress in cancer therapy over recent years, a variety of
therapeutic options are now available. For example,
molecular-targeted therapy is increasingly used, emphasizing
tailored medicine, and various combination therapies are
being administered to further enhance the antitumor effects.
However, it is impossible to evaluate the efﬁcacy and safety
of all possible drug combinations before marketing.
Post-marketing surveillance can be used to collect data from
patients who have received a variety of combination thera-
pies because there are not as many restrictions on the admin-
istration methods used as there are in clinical studies.
Table 2. Continued
Number of
patients
Number of patients
with ADRs (%)
Yes 39 34 (87.2)
Unknown 15 9 (60.0)
Medical history
No 1185 733 (61.9)
Yes 149 107 (71.8)
Unknown 27 18 (66.7)
Complications
No 1052 646 (61.4)
Yes 309 212 (68.6)
Pre-treatment abnormal hepatic function
No 1145 723 (63.1)
Yes 79 58 (73.4)
Unknown 137 77 (56.2)
Pre-treatment abnormal renal function
No 1189 754 (63.4)
Yes 78 60 (76.9)
Unknown 94 44 (46.8)
Previous therapy (surgery)
No 167 96 (57.5)
Yes 1187 758 (63.9)
Unknown 7 4 (57.1)
Previous therapy (radiation therapy)
No 919 551 (60.0)
Yes 426 296 (69.5)
Unknown 16 11 (68.8)
Previous therapy (chemotherapy or hormone therapy)
No 118 70 (59.3)
Yes 1235 784 (63.5)
Unknown 8 4 (50.0)
Initial daily dose of S-1 per body surface area (mg/m
2)
 60 208 115 (55.3)
.60 to  70 516 311 (60.3)
.70 to  80 599 404 (67.4)
.80 38 28 (73.7)
Concomitant drug (chemotherapy or hormone therapy)
No 707 445 (62.9)
Yes 654 413 (63.1)
Concomitant therapy (radiation therapy)
No 1304 822 (63.0)
Yes 57 36 (63.2)
PS, performance status.
1054 Safety of S-1 and trastuzumabTherefore, stratiﬁed analysis of patients given combined drug
treatments using post-marketing surveillance may provide
signiﬁcant information that can complement the pre-
marketing data. In addition, post-marketing surveillance may
help to obtain information from patient subgroups that have
been excluded from clinical studies and highlight previously
unknown adverse drug reactions.
Therefore, we reported the results of the current post-
marketing surveillance of S-1 for the treatment of inoperable
or recurrent breast cancer (covering 2 years from 2006), and
also explored the safety of S-1 when used in combination with
trastuzumab (the most commonly used combination drug).
The most common Grade 3, or higher, severe adverse drug
reactions were: neutrophil count decreased (4.2%), white
blood cell count decreased (3.4%), anemia (including red
blood cell count decreased; 2.5%), diarrhea (1.5%) and plate-
let count decreased (1.4%). In a Phase II clinical study of S-1
in patients with taxane-resistant inoperable or recurrent breast
cancer, the incidence of common Grade 3, or higher, adverse
drug reactions were: neutrophil count decreased (10.9%),
white blood cell count decreased (9.1%), anorexia (5.5%)
and diarrhea (5.5%) (4), illustrating that the incidence of
adverse reactions was lower in the current study.
The presence or absence of allergic disposition was shown
in Fig. 2 as the factor having the strongest impact on the
onset of adverse drug reactions. This was possibly because
many of the subjects with allergic disposition had a history
of hypersensitivity to drugs. The factor with the second
highest odds ratio was baseline renal dysfunction.
Correlationship between lowered renal function and onset of
adverse events was also shown in the risk analysis of
adverse events in the drug use investigation (3758 subjects
with gastric cancer) performed in 1999 (7). It is presumed
that gimeracil is not excreted in patients with renal dysfunc-
tion, because the route of excretion of gimeracil, the active
ingredient of this drug, was via the kidney, and thereby the
blood concentration of 5-FU is maintained at a higher level
compared with patients with normal renal function.
Figure 2. Logistic regression analysis of all adverse drug reactions. PS, performance status.
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of S-1 showed the incidence of hand and foot syndrome
to be 21.8% (12/55 patients); higher than that for other
cancers (4). Therefore, we examined whether a similar
trend was observed in the current surveillance. The inci-
dence of palmar–plantar erythrodysesthesia syndrome was
5.0% higher than that in previous post-marketing surveil-
lances for other cancers [0.2% (8/3808 patients) for gastric
cancer, 0% (0/375 patients) for head and neck cancer and
0.06% (1/1669 patients) for non-small cell lung cancer].
In agreement with the clinical study, the current surveil-
lance study suggests that the incidence of hand and foot
syndrome may be higher in inoperable or recurrent breast
cancer than in other cancers. In addition, hand and foot
syndrome occurred in 37, 30 and 13 out of 80 patients
after the start Cycles 1, 2 and 3, respectively. The inci-
dence was the highest after Cycle 1, but almost as high
after Cycle 2, indicating that patients should be carefully
monitored up to after Cycle 2.
For inoperable or recurrent breast cancer, anthracyclines
and taxanes are the standard chemotherapeutic agents for
HER2-negative breast cancer (5). Chemotherapy combined
with trastuzumab improves survival times in HER2-positive
breast cancer. Response rate with trastuzumab was 55.9%
when used in combination with AC therapy and 41.3% when
used in combination with paclitaxel, in an overseas Phase III
study (8). However, due to the high incidence of peripheral
nerve disorders associated with taxanes (9,10), and bone
marrow depression and phlebitis associated with vinorelbine
(11), there is a need for new regimens that cause fewer
adverse drug reactions.
Table 3. Patient characteristics (S-1 alone vs. S-1 in combination with
trastuzumab)
Patient characteristics Number of patients (%) Fisher’s
exact test
S-1 alone
(n ¼ 679)
S-1 þ trastuzumab
(n ¼ 118)
Age
,65 459 (67.6) 89 (75.4) P ¼ 0.106
 65 220 (32.4) 29 (24.6)
Median 60 56 —
Minimum–maximum 29–92 34–80
PS
0 416 (61.3) 64 (54.2) P ¼ 0.089
1 200 (29.5) 44 (37.3)
2 52 (7.7) 5 (4.2)
3 8 (1.2) 4 (3.4)
4 3 (0.4) 1 (0.8)
Histology
Papillotubular carcinoma 187 (27.5) 29 (24.6) P ¼ 0.731
Solid-tubular carcinoma 149 (21.9) 29 (24.6)
Scirrhous carcinoma 236 (34.8) 40 (33.9)
Other 72 (10.6) 11 (9.3)
Unknown 35 (5.2) 9 (7.6)
Menopause
Before 84 (12.4) 14 (11.9) P ¼ 0.554
After 578 (85.1) 99 (83.9)
Unknown 17 (2.5) 5 (4.2)
Hormone receptor
ER(2) and PgR(2) 303 (44.6) 75 (63.6) P , 0.001
Other 376 (55.4) 43 (36.4)
HER2
0–2 506 (74.5) 22 (18.6) P , 0.001
3 73 (10.8) 95 (80.5)
Unknown 100 (14.7) 1 (0.8)
Complication
No 543 (80.0) 84 (71.2) P ¼ 0.038
Yes 136 (20.0) 34 (28.8)
Previous therapy (chemotherapy or hormone therapy)
No 69 (10.2) 2 (1.7) P ¼ 0.003
Yes 603 (88.8) 115 (97.5)
Unknown 7 (1.0) 1 (0.8)
Initial daily dose of S-1 per body surface area (mg/m
2)
 60 87 (12.8) 14 (11.9) P ¼ 0.745
.60 to  70 264 (38.9) 52 (44.1)
.70 to  80 305 (44.9) 49 (41.5)
.80 23 (3.4) 3 (2.5)
Continued
Table 3. Continued
Patient characteristics Number of patients (%) Fisher’s
exact test
S-1 alone
(n ¼ 679)
S-1 þ trastuzumab
(n ¼ 118)
Number of days of actual treatment with S-1 (days)
Median 59 66 P ¼ 0.084
Mean 58 62
25th–75th percentile 29–84 42–84
Minimum–maximum 1–132 5–142
Number of days of actual treatment with trastuzumab (days)
Median — 8 —
Mean 8
25th–75th percentile 3–11
Minimum–maximum 1–23
The P-value from Wilcoxon’s rank-sum test is shown for PS, initial daily
dose of S-1 per body surface area and duration of treatment with S-1. ER,
estrogen; PgR, progesterone; HER2, human epidermal growth factor
receptor 2.
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bination drug was trastuzumab. The overall incidence of
adverse drug reactions was 63.5% (431/679 patients) in
patients treated with S-1 alone and 55.9% (66/118 patients)
in patients treated with S-1 þ trastuzumab. This suggested
that combination therapy did not increase the incidence of
adverse drug reactions. In addition, the incidence of adverse
drug reactions analyzed according to the patient character-
istics, revealing no particular characteristic resulting in a sig-
niﬁcant difference. In our hospital, a combination of S-1 and
trastuzumab was administered to patients with HER2-
positive metastatic breast cancer, and trastuzumab was found
to have little effect on the pharmacokinetics of S-1 and
caused no serious adverse drug reactions (12).
In conclusion, the current surveillance showed that mono-
therapy with S-1 or combination therapy with S-1 þ trastu-
zumab was well tolerated for inoperable or recurrent breast
cancer patients. However, since this was a post-marketing
surveillance study, efﬁcacy could not be evaluated according
to the RECIST criteria as is common for clinical studies.
Further studies are needed to evaluate the safety and efﬁcacy
of S-1 with or without trastuzumab.
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